Table of Contents
Hepatitis Research and Treatment
Volume 2014, Article ID 307942, 7 pages
http://dx.doi.org/10.1155/2014/307942
Research Article

Serum Inter-Alpha-Trypsin Inhibitor Heavy Chain 4 (ITIH4) in Children with Chronic Hepatitis C: Relation to Liver Fibrosis and Viremia

1Department of Pediatric Hepatology, National Liver Institute, Menofiya University, Shebin El-koom, Menofiya 32511, Egypt
2Department of Microbiology and Immunology, National Liver Institute, Menofiya University, Shebin El-koom, Menofiya 32511, Egypt
3Department of Pediatrics, Faculty of Medicine, Menofiya University, Shebin El-koom, Menofiya 32511, Egypt

Received 5 June 2014; Revised 2 September 2014; Accepted 3 September 2014; Published 14 September 2014

Academic Editor: Piero Luigi Almasio

Copyright © 2014 Mostafa M. Sira et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. P. Valva, P. Casciato, C. Lezama et al., “Serum apoptosis markers related to liver damage in chronic hepatitis C: sFas as a marker of advanced fibrosis in children and adults while M30 of severe steatosis only in children,” PLoS ONE, vol. 8, no. 1, Article ID e53519, 2013. View at Publisher · View at Google Scholar · View at Scopus
  2. N. Mohan, R. P. Gonzalez-Peralta, T. Fujisawa et al., “Chronic hepatitis C virus infection in children,” Journal of Pediatric Gastroenterology and Nutrition, vol. 50, no. 2, pp. 123–131, 2010. View at Publisher · View at Google Scholar
  3. N. Yazigi and W. Balistreri, “Viral hepatitis,” in Nelson Textbook of Pediatrics, R. M. Kliegman, R. E. Behrman, H. B. Jenson, and B. F. Stanton, Eds., vol. 350, pp. 1393–1400, Saunders, Philadelphia, Pa, USA, 19th edition, 2011. View at Google Scholar
  4. E. M. Lehman and M. L. Wilson, “Epidemic hepatitis C virus infection in Egypt: estimates of past incidence and future morbidity and mortality,” Journal of Viral Hepatitis, vol. 16, no. 9, pp. 650–658, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. M. S. El-Raziky, M. El-Hawary, G. Esmat et al., “Prevalence and risk factors of asymptomatic hepatitis C virus infection in Egyptian children,” World Journal of Gastroenterology, vol. 13, no. 12, pp. 1828–1832, 2007. View at Publisher · View at Google Scholar · View at Scopus
  6. A. A. Bravo, S. G. Sheth, and S. Chopra, “Liver biopsy,” The New England Journal of Medicine, vol. 344, no. 7, pp. 495–500, 2001. View at Publisher · View at Google Scholar · View at Scopus
  7. P. Thampanitchawong and T. Piratvisuth, “Liver biopsy: complications and risk factors,” World Journal of Gastroenterology, vol. 5, no. 4, pp. 301–304, 1999. View at Google Scholar · View at Scopus
  8. N. H. Afdhal and D. Nunes, “Evaluation of liver fibrosis: a concise review,” The American Journal of Gastroenterology, vol. 99, no. 6, pp. 1160–1174, 2004. View at Publisher · View at Google Scholar · View at Scopus
  9. S. M. Martínez, G. Crespo, M. Navasa, and X. Forns, “Noninvasive assessment of liver fibrosis,” Hepatology, vol. 53, no. 1, pp. 325–335, 2011. View at Publisher · View at Google Scholar · View at Scopus
  10. L. Yang, K. D. Rudser, L. Higgins et al., “Novel biomarker candidates to predict hepatic fibrosis in hepatitis C identified by serum proteomics,” Digestive Diseases and Sciences, vol. 56, no. 11, pp. 3305–3315, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. B. Gangadharan, R. Antrobus, R. A. Dwek, and N. Zitzmann, “Novel serum biomarker candidates for liver fibrosis in hepatitis C patients,” Clinical Chemistry, vol. 53, no. 10, pp. 1792–1799, 2007. View at Publisher · View at Google Scholar · View at Scopus
  12. M. Piñeiro, M. Andrés, M. Iturralde et al., “ITIH4 (inter-alpha-trypsin inhibitor heavy chain 4) is a new acute-phase protein isolated from cattle during experimental infection,” Infection and Immunity, vol. 72, no. 7, pp. 3777–3782, 2004. View at Publisher · View at Google Scholar · View at Scopus
  13. E. Fries and A. Kaczmarczyk, “Inter-α-inhibitor, hyaluronan and inflammation,” Acta Biochimica Polonica, vol. 50, no. 3, pp. 735–742, 2003. View at Google Scholar · View at Scopus
  14. A. Someya, N. Tanaka, and A. Okuyama, “Inhibition of influenza virus A WSN replication by a trypsin inhibitor, 6-amidino-2-naphthyl p-guanidinobenzoate,” Biochemical and Biophysical Research Communications, vol. 169, no. 1, pp. 148–152, 1990. View at Publisher · View at Google Scholar · View at Scopus
  15. A. Alisi, D. Comparcola, and V. Nobili, “Treatment of chronic hepatitis C in children: is it necessary and, if so, in whom?” Journal of Hepatology, vol. 52, no. 4, pp. 472–474, 2010. View at Publisher · View at Google Scholar · View at Scopus
  16. S. L. Chen and T. R. Morgan, “The natural history of hepatitis C virus (HCV) infection,” International Journal of Medical Sciences, vol. 3, no. 2, pp. 47–52, 2006. View at Google Scholar · View at Scopus
  17. T. Witthöft, B. Möller, K. H. Wiedmann et al., “Safety, tolerability and efficacy of peginterferon alpha-2a and ribavirin in chronic hepatitis C in clinical practice: the German open safety trial,” Journal of Viral Hepatitis, vol. 14, no. 11, pp. 788–796, 2007. View at Publisher · View at Google Scholar · View at Scopus
  18. K. S. Brown, M. J. Keogh, N. Tagiuri et al., “Severe fibrosis in hepatitis C virus- infected patients is associated with increased activity of the mannan-binding lectin (MBL)/MBL-associated serine protease 1 (MASP-1) complex,” Clinical and Experimental Immunology, vol. 147, no. 1, pp. 90–98, 2007. View at Google Scholar
  19. K. Ishak, A. Baptista, L. Bianchi et al., “Histological grading and staging of chronic hepatitis,” Journal of Hepatology, vol. 22, no. 6, pp. 696–699, 1995. View at Publisher · View at Google Scholar · View at Scopus
  20. C.-T. Wai, J. K. Greenson, R. J. Fontana et al., “A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C,” Hepatology, vol. 38, no. 2, pp. 518–526, 2003. View at Publisher · View at Google Scholar · View at Scopus
  21. S. D. Holmberg, M. Lu, L. B. Rupp et al., “Noninvasive Serum fibrosis markers for screening and staging chronic hepatitis C virus patients in a large US cohort,” Clinical Infectious Diseases, vol. 57, no. 2, pp. 240–246, 2013. View at Publisher · View at Google Scholar · View at Scopus
  22. C. Camarero, N. Ramos, A. Moreno, A. Asensio, M. L. Mateos, and B. Roldan, “Hepatitis C virus infection acquired in childhood,” European Journal of Pediatrics, vol. 167, no. 2, pp. 219–224, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. F. Bortolotti, P. Jara, C. Diaz et al., “Posttransfusion and community-acquired hepatitis C in childhood,” Journal of Pediatric Gastroenterology and Nutrition, vol. 18, no. 3, pp. 279–283, 1994. View at Publisher · View at Google Scholar · View at Scopus
  24. J. J. Díaz, K. M. Gura, J. Roda et al., “Aspartate aminotransferase to platelet ratio index correlates with hepatic cirrhosis but not with fibrosis in pediatric patients with intestinal failure,” Journal of Pediatric Gastroenterology and Nutrition, vol. 57, no. 3, pp. 367–371, 2013. View at Publisher · View at Google Scholar · View at Scopus
  25. V. de Lédinghen, B. Le Bail, L. Rebouissoux et al., “Liver stiffness measurement in children using fibroscan: feasibility study and comparison with fibrotest, aspartate transaminase to platelets ratio index, and liver biopsy,” Journal of Pediatric Gastroenterology and Nutrition, vol. 45, no. 4, pp. 443–450, 2007. View at Publisher · View at Google Scholar · View at Scopus
  26. R. K. Sterling, E. Lissen, N. Clumeck et al., “Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection,” Hepatology, vol. 43, no. 6, pp. 1317–1325, 2006. View at Publisher · View at Google Scholar · View at Scopus
  27. P. Valva, P. Casciato, J. M. D. Carrasco et al., “The role of serum biomarkers in predicting fibrosis progression in pediatric and adult hepatitis C virus chronic infection,” PLoS ONE, vol. 6, no. 8, Article ID e23218, 2011. View at Publisher · View at Google Scholar · View at Scopus
  28. A. Hamm, J. Veeck, N. Bektas et al., “Frequent expression loss of Inter-α-trypsin inhibitor heavy chain (ITIH) genes in multiple human solid tumors: a systematic expression analysis,” BMC Cancer, vol. 8, article 25, 2008. View at Publisher · View at Google Scholar · View at Scopus
  29. L. Zhuo, V. C. Hascall, and K. Kimata, “Inter-α-trypsin inhibitor, a covalent protein-glycosaminoglycan-protein complex,” The Journal of Biological Chemistry, vol. 279, no. 37, pp. 38079–38082, 2004. View at Publisher · View at Google Scholar · View at Scopus
  30. H.-G. Wisniewski, D. Naime, J.-C. Hua, J. Vilcek, and B. N. Cronstein, “TSG-6, a glycoprotein associated with arthritis, and its ligand hyaluronan exert opposite effects in a murine model of inflammation,” Pflügers Archiv, vol. 431, no. 6, supplement 2, pp. R225–R226, 1996. View at Publisher · View at Google Scholar · View at Scopus
  31. M. Yano, H. Kumada, M. Kage et al., “The long-term pathological evolution of chronic hepatitis C,” Hepatology, vol. 23, no. 6, pp. 1334–1340, 1996. View at Publisher · View at Google Scholar · View at Scopus
  32. Y. P. Han, “Matrix metalloproteinases, the pros and cons, in liver fibrosis,” Journal of Gastroenterology and Hepatology, vol. 21, supplement 3, no. 3, pp. S88–S91, 2006. View at Publisher · View at Google Scholar · View at Scopus
  33. S. Dooley and P. Ten Dijke, “TGF-β in progression of liver disease,” Cell and Tissue Research, vol. 347, no. 1, pp. 245–256, 2012. View at Publisher · View at Google Scholar · View at Scopus
  34. R. I. Lindstad, I. Sylte, S.-O. Mikalsen, P. O. Seglen, E. Berg, and J.-O. Winberg, “Pancreatic trypsin activates human promatrix metalloproteinase-2,” Journal of Molecular Biology, vol. 350, no. 4, pp. 682–698, 2005. View at Publisher · View at Google Scholar · View at Scopus
  35. M. E. Duncan, J. P. Richardson, G. I. Murray, W. T. Melvin, and J. E. Fothergill, “Human matrix metalloproteinase-9: activation by limited trypsin treatment and generation of monoclonal antibodies specific for the activated form,” European Journal of Biochemistry, vol. 258, no. 1, pp. 37–43, 1998. View at Publisher · View at Google Scholar · View at Scopus
  36. K. Hashimoto, Y. Nagao, K. Kato, Y. Mori, and A. Ito, “Human urinary trypsin inhibitor inhibits the activation of promatrix metalloproteinases and proteoglycans release in rabbit articular cartilage,” Life Sciences, vol. 63, no. 3, pp. 205–213, 1998. View at Publisher · View at Google Scholar · View at Scopus
  37. M. Okuno, K. Akita, H. Moriwaki et al., “Prevention of rat hepatic fibrosis by the protease inhibitor, camostat mesilate, via reduced generation of active TGF-β,” Gastroenterology, vol. 120, no. 7, pp. 1784–1800, 2001. View at Publisher · View at Google Scholar · View at Scopus
  38. G. Esmat, M. El Raziky, M. El Kassas, M. Hassany, and M. E. Gamil, “The future for the treatment of genotype 4 chronic hepatitis C,” Liver International, vol. 32, supplement 1, pp. 146–150, 2012. View at Publisher · View at Google Scholar · View at Scopus
  39. H. A. El-Araby, M. M. Sira, B. E. Behairy, A. O. El-Refaie, and E. M. Ghoneim, “Interferon induction regimen for chronic hepatitis C genotype 4 in Egyptian children,” Journal of Pediatric Infectious Diseases, vol. 5, no. 3, pp. 233–241, 2010. View at Publisher · View at Google Scholar · View at Scopus
  40. A. Rosenquist, B. Samuelsson, P. O. Johansson et al., “Discovery and development of simeprevir (TMC435), a HCV NS3/4A protease inhibitor,” Journal of Medicinal Chemistry, vol. 57, no. 5, pp. 1673–1693, 2014. View at Publisher · View at Google Scholar · View at Scopus
  41. K. L. Berger, I. Triki, M. Cartier et al., “Baseline hepatitis C virus (HCV) NS3 polymorphisms and their impact on treatment response in clinical studies of the HCV NS3 protease inhibitor faldaprevir,” Antimicrobial Agents and Chemotherapy, vol. 58, no. 2, pp. 698–705, 2014. View at Publisher · View at Google Scholar · View at Scopus
  42. B. L. Pearlman and C. Ehleben, “Hepatitis C genotype 1 virus with low viral load and rapid virologic response to peginterferon/ribavirin obviates a protease inhibitor,” Hepatology, vol. 59, no. 1, pp. 71–77, 2014. View at Publisher · View at Google Scholar · View at Scopus
  43. O. P. Zhirnov, A. V. Ovcharenko, and A. G. Bukrinskaya, “Myxovirus replication in chicken embryos can be suppressed by aprotinin due to the blockage of viral glycoprotein cleavage,” Journal of General Virology, vol. 66, part 7, pp. 1633–1638, 1985. View at Publisher · View at Google Scholar · View at Scopus
  44. M. Hosoya, S. Matsuyama, M. Baba, H. Suzuki, and S. Shigeta, “Effects of protease inhibitors on replication of various myxoviruses,” Antimicrobial Agents and Chemotherapy, vol. 36, no. 7, pp. 1432–1436, 1992. View at Publisher · View at Google Scholar · View at Scopus
  45. N. Dimasi, F. Martin, C. Volpari et al., “Characterization of engineered hepatitis C virus NS3 protease inhibitors affinity selected from human pancreatic secretory trypsin inhibitor and minibody repertoires,” Journal of Virology, vol. 71, no. 10, pp. 7461–7469, 1997. View at Google Scholar · View at Scopus